Search research articles
Contact Us
Filters
Showing results (31-40 of 56) with videos related to
Page
of 6
Sort By:
Oncoimmunology
|
August 8, 2020
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation
Ieva Saulite, Desislava Ignatova, Yun-Tsan Chang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2021
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases
Marie-Luise Hilbers, Florentia Dimitriou, Peter Lau, et al.
Cell Reports. Medicine
|
June 28, 2024
Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance
Jelena Vasilevska, Phil Fang Cheng, Julia Lehmann, et al.
Skin Health and Disease
|
December 3, 2024
Gender differences in melanoma awareness, diagnosis and treatment: Patient-reported data from a multicentre survey in Switzerland
Johanna Mangana, Cristina Lamos, Berna C Özdemir, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 14, 2023
The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres
Alexander Troesch, Magdalena Hoellwerth, Stephan Forchhammer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 5, 2023
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, et al.
Journal for Immunotherapy of Cancer
|
July 7, 2022
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
Ines Pires da Silva, Danny Zakria, Tasnia Ahmed, et al.
The British Journal of Dermatology
|
July 6, 2023
Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in patients with leukaemic cutaneous T-cell lymphoma
Yi-Chien Tsai, Tanja Schlaepfer, Desislava Ignatova, et al.
Scientific Reports
|
August 4, 2025
Gene expression and molecular pathway analyses differentiate immunotherapy-induced myositis from spontaneous dermatomyositis
Magdalena Röckel, Luca Musella, Corinna Preusse, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 20, 2018
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Alvaro Moreira, Carmen Loquai, Claudia Pföhler, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 56) with videos related to
Sort By:
Page
of 6
Oncoimmunology
|
August 8, 2020
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation
Ieva Saulite, Desislava Ignatova, Yun-Tsan Chang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2021
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases
Marie-Luise Hilbers, Florentia Dimitriou, Peter Lau, et al.
Cell Reports. Medicine
|
June 28, 2024
Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance
Jelena Vasilevska, Phil Fang Cheng, Julia Lehmann, et al.
Skin Health and Disease
|
December 3, 2024
Gender differences in melanoma awareness, diagnosis and treatment: Patient-reported data from a multicentre survey in Switzerland
Johanna Mangana, Cristina Lamos, Berna C Özdemir, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 14, 2023
The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres
Alexander Troesch, Magdalena Hoellwerth, Stephan Forchhammer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 5, 2023
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, et al.
Journal for Immunotherapy of Cancer
|
July 7, 2022
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
Ines Pires da Silva, Danny Zakria, Tasnia Ahmed, et al.
The British Journal of Dermatology
|
July 6, 2023
Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in patients with leukaemic cutaneous T-cell lymphoma
Yi-Chien Tsai, Tanja Schlaepfer, Desislava Ignatova, et al.
Scientific Reports
|
August 4, 2025
Gene expression and molecular pathway analyses differentiate immunotherapy-induced myositis from spontaneous dermatomyositis
Magdalena Röckel, Luca Musella, Corinna Preusse, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 20, 2018
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Alvaro Moreira, Carmen Loquai, Claudia Pföhler, et al.
Page
of 6